Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus. A 52-week Randomised, Open-label, Active-controlled Trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Semaglutide (Primary) ; Empagliflozin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 2
- Sponsors Novo Nordisk
- 30 Jun 2017 Planned End Date changed from 13 Mar 2018 to 12 Mar 2018.
- 10 Jun 2017 Biomarkers information updated
- 09 Mar 2017 Status changed from recruiting to active, no longer recruiting.